A JAKi CHAT: Shared Decision-Making in RA
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. John Cush
Tweet
Mrinalini Dey
Tweet
JAKi vs TNFi in higher-CV-risk RA: target trial emulation of 17607 matched pairs found MACE HR 1.02, but higher mortality (HR 1.21) and HF admission (HR 1.11). Findings refine results from ORAL Surveillance and support individualized JAKi agent selection #1900 @Rheumnow #ACR26 https://t.co/uDuOCPa6bf
Licia Mota
Tweet
Can AI help discover the next generation of oral immunomodulators?
#ACR26 Abst 066: AI-guided discovery identified 66882BD, a small-molecule TL1A antagonist with confirmed target binding and functional activity.
A promising step toward oral TL1A-targeted therapies
@RheumNow https://t.co/iGFlVmxOtt
Janet Pope
Tweet
#GCA #Flares in year 2
Of #upadacitinib in remission
at end of yr 1
Randomized to
UPA-UPA
Vs
UPA-PBO
No surprise, on Yr2 PBO
⬆️flares
⬆️pred
⬆️CRP & ESR if flare but higher in no Rx group
Take home Rx likely needed for 2 yrs in #GCA
#ACR26 @RheumNow @ACRheum
#abst1892
sheila
Tweet
In this real-world cohort study using TriNetX data by Dr Singh et al, SGLT2i use in non-DM LN showed lower 3yr cumulative event rates for ESRD/dialysis, heart failure, AKI & high gr proteinuria
Promising data for SGLT2i in non-DM LN. More studies needed.
@RheumNow #ACR26 Abs1867 https://t.co/FPe5ZmAxYN
RheumAI
Tweet
¡Notición de acceso! La FDA tiene genéricos de tofacitinib (IR 5/10 mg, XR 11/22 mg y solución 1 mg/mL). Tras el vencimiento de patente (jun 2026) hay ola comercial en EE. UU.
@RheumNow: el 5 mg ~US$25/mes en Mark Cuban Cost Plus Drugs (frasco 60). Verificar precio al ordenar. https://t.co/pVfGsJyIfN
Richard Conway
Tweet
Natalucci et al. Case series combination JAKi and bDMARD in multi-refractory RA (6 patients) (and 1 PsA, 1 SpA) @RheumNow #ACR26 Abstr#1403 https://t.co/vGrwzbd5y1
Adela Castro
Tweet
Post-hoc analysis of the phase II/III trial of ivarmacitinib 4 mg (a selective JAK1 inhibitor) in 178 patients with active AS. At week 12, 34% reached ASAS40.
Shorter disease duration: higher odds of response (OR 0.94 per year, p=0.019)
-Female vs male: OR 2.35 (95% CI
Brian Jaros, MD
Tweet
Upadacitinib beats out Deucravacitinib in PsA
SELECT-PsA pt matched to POETYK-PsA pt
Week 12 UPA wins vs. week 16 DEU at:
- ACR 20
- ACR 50
- ACR 70
- MDA
Surprisingly similar safety signals but short-term timepoint
#ACR26 @RheumNow #Abst1309 https://t.co/Z3CQ7DcmZj
sheila
Tweet
For D2M axSpA, new ACR/SAA/SPARTAN guidelines strongly recommends switching to a 3rd rx w/ diff MOA than TNFi, IL-17 or JAKi & cond. recommends using a higher dose or giving dual b/tsDMARD
For D2M, consider other causes of back pain, mimics; check non-adherence
@RheumNow #ACR26 https://t.co/4N5lKUXhLS
Dr. John Cush
Tweet
ACR 2026 – Biotech and Mid-Size Companies Bet on Novel Mechanisms
ACR Convergence 2026 is crowded with first-in-class mechanisms: an oral IL-23 receptor peptide, FcRn blockade, a JAK head-to-head and a wave of cell depletion therapies.
https://t.co/hhUX2ZXJlp https://t.co/rvpzdh56H7
Brian Jaros, MD
Tweet
Should we triage TAK tx by age?
2 TAK cohorts
TNFi responders: YOUNGER - mean age 23
Toci responders: OLDER - mean age 35
How does age change disease pathophys and are older patients closer to a GCA-spectrum disease?
Potentially practice changing
#ACRbest @RheumNow #Abst1124 https://t.co/JxAsRm8Q4M
Brian Jaros, MD
Tweet
Can we add JAKi to our TAK arsenal?
Systemic review/meta-analysis of JAK treated TAK patients:
Overall response rate
- 86% at Mo 6
- 76.6% at Mo 12
Hugely encouraging # but need more info about specifics of their endpoint
#Abst1123 @RheumNow #ACR26 https://t.co/u9Sas0DBMe
David Liew
Tweet
PD-1 agonists & RA:
peresolimab ph2b failed safety/efficacy
rosnilimab ph2b better for both
how confident on efficacy?
translational shows it's deeper where it counts
do differences matter?
(membrane proximal, ligand sparing, ?dual action)
we will see
ABST0868 #ACR26 @RheumNow https://t.co/P3FjrUKhwE
Dr. John Cush
Tweet
TARA study from China - Ph2 H2H Girocitinib (JAK1/TYK2i) vs Tofacitinib in active RA refractory to bDMARDS. 459 pts, ACR50 @wk 24 Giro 73% vs Tofa 49% (p<0.0001), also superior at ACR20, ACR70, DAS remission, CDAI<10. H.Zoster 3%. Abst#LB21 #ACR26 https://t.co/JZLjQx4vSa https://t.co/51gaIOKTWf
Janet Pope
Tweet
‘Strong’ data in #myositis
#0904 #Efgartigimod ⬇️Igs &#Abs
LB +ph3 #RCT -👍on Wed
#0905 #nipocalimab in #IIM also #FcRn
#0906 #ruxolitinib ⬆️#survival in severe #MDA5 - but not RCT
#0907 +RCT IIM #Brepocitinib
☑️clinical remission
☑️HAQ
☑️LDA
#ACR26 #ACRbest
@RheumNow
Antoni Chan MD (Prof)
Tweet
ATTRA, Czech registry: 190 patients with difficult to manage axSpA after two mechanisms. 46% had received two or more TNFi first, and 41% returned to a TNFi after the second failure. Similar out study of 22 years Abstract#0352. Key finding: JAKi gave a faster response than IL17i
Antoni Chan MD (Prof)
Tweet
UPSTAND, upadacitinib in axSpA (post hoc): a 30% fall in back pain at week 1 was associated with ASDAS LDA (OR 2.21) and BASDAI below 4 (OR 3.98) at week 52. Key finding: early pain improvement was associated with better long term disease activity, fatigue, function and sleep. https://t.co/qSXjJMddiO
Eric Dein
Tweet
#ACR26 @RheumNow
Ab#0478
Baricitinib in 84 RA-ILD pts
Improved/stable dyspnea 83%, HRCT 68% at mean f/u 48 mos. DAS28-ESR from 4.3 to 2.8, median pred from 5 mg/d to 0 https://t.co/HTjUY7mHkV
Richard Conway
Tweet
Munoz et al. Baricitinib in RA-ILD. 84 patients. FVC and DLCO remained stable through 36 months. Dyspnea and HRCT findings improved or remained stable in 83% and 68% of patients at 48 months. @RheumNow #ACR26 Abstr#0478 https://t.co/yDQCiR6FHN
Akhil Sood MD, MS
Tweet
Abstract 0875: Nipocalimab (FcRn blocker) in SLE – Phase 2 JASMINE trial
Nipocalimab 15 mg/kg IV q2w vs Placebo:
SRI-4 wk24: 53.5 vs 46.7% (1° EP)
SRI-4 wk52: 53.6 vs 39.7%
LLDAS wk52: 37.5 vs 20.5%
↓IgG, anti-dsDNA; ↑C3 by Wk 52
Well tolerated
#ACR26 @RheumNow
David Liew
Tweet
RA-ILD: what's the best b/tSDMARD?
this Spanish multicenter observational cohort looked at abatacept vs JAKi - no difference
so many analyses, the same feeling persists:
disease control is what matters
the method is of secondary importance at best
ABST0838 #ACR26 @RheumNow https://t.co/qsEUfqCGLY
David Liew
Tweet
My rule with HZ vaccination with JAKi:
just get it in
Spanish RA/SpA cohort starting JAKi, n=101
humoral immunogenicity goes up, no matter the exposure
don't let perfect be the enemy of good
ABST0681 #ACR26 @RheumNow https://t.co/cMjvRZMON3
sheila
Tweet
YIR: SEC arms (300mg and 150mg) achieved sustained remission vs PBO in PMR.
SEC showed steroid-sparing effects, additional tx option for PMR.
@RheumNow #ACR26 https://t.co/0w9FwDu9mu
Dr. John Cush
Tweet
Japanese retrospective cohort systemic sclerosis study shows adjunctive tofacitinib improved ower esophageal sphincter pressures (LESP). 50 SSc pts w/ esophageal Sxs Rx w/ Tofa or PBO x 24 wks. Tofa assoc w/ signif LESP increases & lower mRSS & IL-6 levels https://t.co/NNREBddiOi https://t.co/acVOfoorRP
Therapeutic Updates
Experts Dr. Jeffrey Curtis and Dr. Kevin Winthrop discuss best practices for shared decision-making, how to talk with patients about the risks of poorly controlled RA, and ways to use a new tool for visualizing the long-term safety of a JAKi.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
Long-Term Safety of a JAKi in Clinical Trial and Real-World Settings Across >21,000 Patient-Years
Podcasts
PsA Topic Podcast compilation
EULAR 2026 Daily Podcast Day 4c-
EULAR 2026 Daily Podcast Day 4a